News

Microbion Announces Positive Topline Results from Phase 2 Study of Topical Pravibismane for Moderately Infected Diabetic Foot Ulcers

Microbion Receives Award at Advanced Wound Care Summit USA’s Innovation Showcase

Microbion Selected to Present at Advanced Wound Care Summit USA

Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal

Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections

Microbion CEO to Participate in Panel Discussion at BioFuture 2023

Microbion Presented New Pravibismane Data Against Mycobacteroides abscessus at the 6th World Bronchiectasis and NTM Conference

Microbion to Present Design of Ongoing Phase 2 Study Treating Diabetic Foot Ulcer Infections at the 2023 Military Health System Research Symposium

Microbion to Present New Data Demonstrating that Pravibismane Disrupts Bacterial Bioenergetics at ASM Microbe 2023

Microbion Corp. Presents a Poster on Pravibismane’s Activity Against Diabetic Foot Infection Patient Isolates

Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections

Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections

Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference

Microbion Corporation Announces Poster Highlighting Pravibismane Activity Against Common Cystic Fibrosis Pulmonary Pathogens to be Presented at the North American Cystic Fibrosis Conference 2022

Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022

Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane

Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity Against NTM Causing Intracellular Infections, to be Presented at the Colorado Mycobacteria Conference 2022

Microbion Corporation Announces Granting of a US Patent for the Use of Topical Pravibismane for Diabetic Foot Ulcer Infections

Microbion Corporation Appoints Robert A. Gillam as Chairman of Microbion’s Board of Directors

Microbion Corporation Receives Additional Funding Support from the Cystic Fibrosis Foundation to Speed Advancement of Inhaled Pravibismane

5N Plus Acquires Stake in Microbion and Secures Drug Substance Manufacturing Rights

Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF

Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA

Microbion Corporation Announces Litigation Settlement Agreement, Including a License Agreement, with NYU Langone Health

Microbion Corporation Announces Results from Randomized, Double Blind, Placebo-Controlled Phase 1b Trial of Pravibismane (MBN-101) for Treatment of Moderate to Severe Chronic Infected Diabetic Foot Ulcers

Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: Pravibismane

Microbion Corporation to Present Data Highlighting Broad Spectrum Activity of BisEDT at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Quark Venture & GF Securities Invest US$25M in Microbion to Advance New Class of Drugs

MBN-101 Received FDA Fast Track Designation: Adjunctive Treatment of Diabetic Foot Ulcer Infections

Microbion Corporation Announces First Patient Treated in Phase 2a Orthopedic Infection Trial

MBN-101 Received FDA QIDP Designation for Adjunctive Treatment of Moderate & Severe DFI

Bozeman pharmaceutical company awarded $17M in grants for drug development

Bozeman's Microbion is fighting to save lives - Inside the war on antimicrobial resistance